12:00 AM
 | 
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zenapax daclizumab: Phase II; marketed to prevent acute organ rejection following renal transplant

Zenapax showed efficacy in a trial of 43 allogeneic bone marrow transplant recipients. The first 24 patients received 1 mg/kg Zenapax on days 1, 8, 15, 22 and 29. Among these patients, 29...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >